Regeneron Pharmaceuticals Inc. buy Canaccord Genuity Group Inc.
Summary
This prediction is currently active. With a performance of 31.10% the BUY prediction by Canaccord_Genuity_Gr is a big success. This prediction currently runs until 21.08.24. The prediction end date can be changed by Canaccord_Genuity_Gr at any time. Canaccord_Genuity_Gr has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | 1.662% | 1.662% |
iShares Core DAX® | 0.410% | -2.543% |
iShares Nasdaq 100 | -2.154% | 4.721% |
iShares Nikkei 225® | -0.066% | -0.307% |
iShares S&P 500 | -0.527% | 3.848% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren